CHEPLAPHARM has acquired the commercial rights for Xeloda® (capecitabin) in China from Roche. In early 2022, CHEPLAPHARM already obtained the global rights (excluding Japan and China) for the highly effective antineoplastic agent. By adding China, CHEPLAPHARM strengthens its oncology portfolio and expands its presence within the second largest pharmaceutical market.
Xeloda® was approved in China as prescription medication in 1997. In 2007, Shanghai Roche Pharmaceuticals has received China’s State FDA approval for the treatment of metastatic breast and colorectal cancers, as well as of advanced gastric cancer.
Today, Xeloda® is registered in 80 countries and is essential for the aforementioned forms of cancer, belonging to the most frequently diagnosed cancers worldwide.
As a leading acquirer of originator brands from big pharma companies, CHEPLAPHARM has built up a strong and diversified portfolio of well-established medicines over the last 20 years. “The acquisition of Xeloda® in China is an enrichment to our oncology portfolio and represents a significant step in our strategy to expand our global footprint in the second largest pharmaceutical market. We look forward to intensifying the collaboration with our Chinese partners.”, says Edeltraud Lafer, CEO of CHEPLAPHARM.
The transaction includes product registrations and intellectual property. It does not include any transfer of manufacturing facilities or employees.
CHEPLAPHARM is a fast-growing pharmaceutical company, headquartered in Greifswald, Germany, offering branded and niche products worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy.
Please refer to www.cheplapharm.com for additional information.
CHEPLAPHARM ǀ Ziegelhof 24 ǀ 17489 Greifswald ǀ presse(at)cheplapharm.com